Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Compulsory licensing of patented pharmaceutical inventions: evaluating the options</title><author><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">19493070</idno><idno type="pmc">2893582</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2893582</idno><idno type="RBID">PMC:2893582</idno><idno type="doi">10.1111/j.1748-720X.2009.00369.x</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000282</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Compulsory licensing of patented pharmaceutical inventions: evaluating the options</title><author><name sortKey="Reichman, Jerome H" sort="Reichman, Jerome H" uniqKey="Reichman J" first="Jerome H." last="Reichman">Jerome H. Reichman</name></author></analytic><series><title level="j">The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics</title><idno type="ISSN">1073-1105</idno><idno type="eISSN">1748-720X</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.</p></div></front></TEI><pmc article-type="research-article" xml:lang="EN"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">9315583</journal-id><journal-id journal-id-type="pubmed-jr-id">2522</journal-id><journal-id journal-id-type="nlm-ta">J Law Med Ethics</journal-id><journal-title>The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics</journal-title><issn pub-type="ppub">1073-1105</issn><issn pub-type="epub">1748-720X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">19493070</article-id><article-id pub-id-type="pmc">2893582</article-id><article-id pub-id-type="doi">10.1111/j.1748-720X.2009.00369.x</article-id><article-id pub-id-type="manuscript">NIHMS204056</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Compulsory licensing of patented pharmaceutical inventions: evaluating the options</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Reichman</surname><given-names>Jerome H.</given-names></name><aff id="A1">Bunyan S. Womble Professor of Law, Duke University School of Law, Durham, N.C</aff></contrib></contrib-group><pub-date pub-type="nihms-submitted"><day>26</day><month>5</month><year>2010</year></pub-date><pub-date pub-type="ppub"><season>Summer</season><year>2009</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>7</month><year>2010</year></pub-date><volume>37</volume><issue>2</issue><fpage>247</fpage><lpage>263</lpage><abstract><p id="P1">In this Comment, the author traces the relevant legislative history pertaining to compulsory licensing of patented pharmaceuticals from the TRIPS (Trade-Related Aspects of Intellectual Property Rights) Agreement of 1994 to the 2003 waiver to, and later proposed amendment of, article 31, which enables poor countries to obtain needed medicines from other countries that possess manufacturing capacity. The Comment then evaluates recent, controversial uses of the relevant legislative machinery as viewed from different critical perspectives. The Comment shows how developing countries seeking access to essential medicines can collaborate in ways that would avoid undermining incentives to innovation and other social costs attributed to compulsory licensing. It ends by defending the legality of recent measures taken to promote public health in developing countries, and by reminding developed countries that unilateral retaliation against such measures is demonstratably illegal under WTO foundational law and jurisprudence.</p></abstract><contract-num rid="HG1">P50 HG003391-050003
||HG</contract-num><contract-sponsor id="HG1">National Human Genome Research Institute : NHGRI</contract-sponsor></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Belgique/explor/OpenAccessBelV2/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0002820 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0002820 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Belgique
|area= OpenAccessBelV2
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.25. |  |